VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
BIOXBioceres Crop Solutions Corp.
$0.37$24M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBIOXP/E History

BIOX logoBioceres Crop Solutions Corp. (BIOX) P/E Ratio History

Deep Value

Trading at -0.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2018–2025

Current P/E (TTM)
-0.5x
-100% vs 5Y avg
5Y Avg P/E
152.1x
Median 75.5x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
-0.5x
Min39.1xMedian75.5xMax472.0x
TTM EPS$-3.72
Price$0.37
Earnings YieldN/A
EPS Growth (1Y)-1704.7%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Bioceres Crop Solutions Corp. (BIOX) trades at a price-to-earnings ratio of -0.5x, with a stock price of $0.37 and trailing twelve-month earnings per share of $-3.72.

The current P/E is 100% below its 5-year average of 152.1x. Over the past five years, BIOX's P/E has ranged from a low of 39.1x to a high of 472.0x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Basic Materials sector median P/E of 23.6x, BIOX trades at a 102% discount to its sector peers. The sector includes 123 companies with P/E ratios ranging from 1.0x to 184.0x.

Relative to the broader market, BIOX trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BIOX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

BIOX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Basic Materials
-0.5vs23.6
-102%
Below Sector
vs. S&P 500
-0.5vs24.4
-102%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -1705% EPS growth (1Y)

BIOX P/E vs Peers

Seeds and crop genetics peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
CTVA logoCTVACorteva, Inc.
$53B49.14.11+23%
HALO logoHALOHalozyme Therapeutics, Inc.
$8B26.81.17-25%
DE logoDEDeere & Company
$159B31.91.95-28%
CF logoCFCF Industries Holdings, Inc.
$16B11.5Lowest0.26Best+33%
MOS logoMOSThe Mosaic Company
$7B13.5-+209%
NTR logoNTRNutrien Ltd.
$30B13.30.32+249%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

BIOX Historical P/E Data (2018–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q2-$6.08$0.03210.4x+38%
FY2025 Q1Sep 30 2024$7.87$0.03271.4x+78%
FY2024 Q4Jun 30 2024$11.21$0.04258.9x+70%
FY2024 Q3Mar 31 2024$12.66$0.04305.8x+101%
FY2024 Q2Dec 31 2023$13.73$0.3539.1x-74%
FY2024 Q1Sep 30 2023$11.29$0.2251.4x-66%
FY2023 Q4Jun 30 2023$13.36$0.3044.4x-71%
FY2023 Q3Mar 31 2023$11.61$0.2253.2x-65%
FY2022 Q2Dec 31 2021$14.14$0.09152.4x+0%
FY2022 Q1-$13.50$0.03472.0x+210%
FY2021 Q1Sep 30 2020$5.36$0.0959.4x-61%
FY2020 Q4-$6.06$0.0875.5x-50%
FY2019 Q2-$10.09$0.1662.9x-59%
FY2019 Q1Oct 31 2018$9.75$0.1563.7x-58%
FY2018 Q4-$9.69$0.06161.5x+6%

Average P/E for displayed period: 152.1x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

8+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

BIOX — Frequently Asked Questions

Quick answers to the most common questions about buying BIOX stock.

What is BIOX's P/E ratio?

Bioceres Crop Solutions Corp. (BIOX) trailing twelve-month P/E ratio is -0.5x, based on TTM diluted EPS of $-3.72. The 5-year average P/E is 152.1x and the historical range spans 39.1x to 472.0x.

Is BIOX stock overvalued or undervalued?

BIOX trades at -0.5x P/E, below its 5-year average of 152.1x. At the 0th percentile of its historical range (39.1x–472.0x), the stock is priced at a discount to its own history.

Is BIOX stock expensive?

No, BIOX is not expensive on a historical basis. The current P/E of -0.5x is below the 5-year average of 152.1x and sits at the 0th percentile of its valuation range.

What is BIOX's historical P/E range?

Over the past 5 years, BIOX's P/E ratio has ranged from 39.1x to 472.0x, with a median of 75.5x and an average of 152.1x. The current P/E of -0.5x places the stock at the 0th percentile of this range. Full historical data spans 2018–2025.

How does BIOX's P/E compare to the S&P 500?

BIOX trades at -0.5x P/E versus the S&P 500 median of 24.4x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.

How does BIOX's valuation compare to Basic Materials peers?

Bioceres Crop Solutions Corp. P/E of -0.5x compares to the Basic Materials sector median of 23.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is BIOX's PEG ratio?

BIOX PEG ratio is N/A, based on a P/E of -0.5x and EPS growth of -1704.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is BIOX's earnings yield?

BIOX earnings yield is N/A, the inverse of its -0.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

BIOX P/E Ratio History (2018–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current210.4x
Period Avg152.1x
Range39.1x - 472.0x
Change+30%
15 quartersJul 31, 2018 - Dec 31, 2024